KR20240110013A - Akr1c3-활성화 dna 알킬화제 및 이의 의학적 적용 - Google Patents

Akr1c3-활성화 dna 알킬화제 및 이의 의학적 적용 Download PDF

Info

Publication number
KR20240110013A
KR20240110013A KR1020247018893A KR20247018893A KR20240110013A KR 20240110013 A KR20240110013 A KR 20240110013A KR 1020247018893 A KR1020247018893 A KR 1020247018893A KR 20247018893 A KR20247018893 A KR 20247018893A KR 20240110013 A KR20240110013 A KR 20240110013A
Authority
KR
South Korea
Prior art keywords
compound
cancer
compounds
tumor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247018893A
Other languages
English (en)
Korean (ko)
Inventor
안롱 리
지안신 두안
판잉 맹
티안양 치
텡 멍
멍윈 장
Original Assignee
아센타위츠 파마슈티컬즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아센타위츠 파마슈티컬즈 리미티드 filed Critical 아센타위츠 파마슈티컬즈 리미티드
Publication of KR20240110013A publication Critical patent/KR20240110013A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • C07C201/06—Preparation of nitro compounds
    • C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
    • C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
    • C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/564—Three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020247018893A 2021-11-05 2021-11-05 Akr1c3-활성화 dna 알킬화제 및 이의 의학적 적용 Pending KR20240110013A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2021/129077 WO2023077452A1 (zh) 2021-11-05 2021-11-05 Akr1c3活化的dna烷化剂及其医药用途

Publications (1)

Publication Number Publication Date
KR20240110013A true KR20240110013A (ko) 2024-07-12

Family

ID=86240506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247018893A Pending KR20240110013A (ko) 2021-11-05 2021-11-05 Akr1c3-활성화 dna 알킬화제 및 이의 의학적 적용

Country Status (6)

Country Link
EP (1) EP4428138A4 (https=)
JP (1) JP2024539385A (https=)
KR (1) KR20240110013A (https=)
CN (1) CN118201940A (https=)
TW (1) TW202320804A (https=)
WO (1) WO2023077452A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114106042B (zh) * 2021-11-12 2022-09-16 深圳艾欣达伟医药科技有限公司 一种氘代化合物及其制备方法和应用
KR20260009356A (ko) 2023-05-11 2026-01-19 아센타위츠 파마슈티컬즈 리미티드 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법
WO2025140580A1 (zh) * 2023-12-28 2025-07-03 深圳艾欣达伟医药科技有限公司 化合物晶型

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI674258B (zh) * 2015-03-10 2019-10-11 大陸商深圳艾欣達偉醫藥科技有限公司 Ｄｎａ烷化劑
WO2016161342A2 (en) * 2015-04-02 2016-10-06 Threshold Pharmaceuticals, Inc. Nitrobenzyl derivatives of anti-cancer agents
EP3390415B1 (en) * 2015-11-16 2020-02-26 Obi Pharma, Inc. (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation
WO2020228685A1 (zh) * 2019-05-13 2020-11-19 深圳艾欣达伟医药科技有限公司 含氟化合物及抗癌医药用途
US20220387345A1 (en) * 2019-11-01 2022-12-08 Ascentawits Pharmaceuticals, Ltd. Anti-cancer compounds acting as non-pgp substrate
TWI837402B (zh) * 2019-12-20 2024-04-01 大陸商深圳艾欣達偉醫藥科技有限公司 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途

Also Published As

Publication number Publication date
TW202320804A (zh) 2023-06-01
CN118201940A (zh) 2024-06-14
EP4428138A1 (en) 2024-09-11
WO2023077452A1 (zh) 2023-05-11
EP4428138A4 (en) 2025-08-27
JP2024539385A (ja) 2024-10-28

Similar Documents

Publication Publication Date Title
US20230339991A1 (en) Hypoxia-activated dna alkylating agent and medical use thereof
KR20240110013A (ko) Akr1c3-활성화 dna 알킬화제 및 이의 의학적 적용
Antoszczak et al. Iron-sensitive prodrugs that trigger active ferroptosis in drug-tolerant pancreatic cancer cells
LoRusso et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
JP2026053650A (ja) 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害
Kruczynski et al. Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system
EA027987B1 (ru) Оксазолидин-2-онпиримидиновые производные
Shan et al. First total synthesis, antitumor evaluation and target identification of mornaphthoate E: a new tubulin inhibitor template acting on PI3K/Akt signaling pathway
Ausili et al. A comparison of the location in membranes of curcumin and curcumin-derived bivalent compounds with potential neuroprotective capacity for Alzheimer’s disease
Xu et al. A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy
US20220168431A1 (en) Methods of treating cancer using trimetazidine-based compounds
Ingraham IV et al. Bypassing Blood‐Brain Barrier and Glucose Dependency of Anti‐Glioblastoma Drug Candidates Targeting Mitochondrial Respiration
WO2025026214A1 (zh) 治疗p53基因突变或缺陷阴性癌症、肿瘤患者
CN121311605A (zh) 通过kras突变来关联akr1c3酶表达水平及医药用途
EP4582104A1 (en) Combination drug
Zhu et al. Discovery of thioetomidate derivatives as rapid recovery hypnotics without adrenocortical suppression
Sheng et al. PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts
Wang et al. Improved Antitumor Efficiency of N4-Tetradecyloxycarbonyl Gemcitabine-Loaded Liposomes for Pancreatic Cancer Chemotherapy
Teixeira Internship Reports and Monograph Entitled “Click Chemistry Derived 1, 2, 3-Triazole Hybrids in Lung Cancer Therapy”
JP2025500434A (ja) γサブユニットを標的とするミトコンドリアＡＴＰ阻害剤は転移を予防する
Mei et al. Glycosylated Shikonin derivative Z-1-2 inhibits triple-negative breast Cancer growth and metastasis through glycerophospholipid metabolism modulation
WO2026006838A1 (en) Sulfonyl-triazoles useful as covalent activators of the glycolytic enzyme pfkl for t cell activation
WO2025240977A1 (en) Compositions of sulfonyl-purine compounds and use thereof for modifying functional protein sites
US20220409581A1 (en) Methods and compositions for treatment of solid tumors using f16 isoindole small molecules
Cheeseman et al. Phase I and pharmacologic study of CT-2584 HMS, a modulator of phosphatidic acid, in adult patients with solid tumours

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241030

Comment text: Request for Examination of Application